Core Scientific Quarterly Cash Flow Statement
NASDAQ: CORZFinanceFinance: Consumer ServicesUSD
15.41+0.05 (+0.33%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Core Scientific free cash flow
In the quarter ended Jun 30, 2026, Core Scientific generated -$18.9 million of operating cash flow and spent $565.0 million on capital expenditures. That left free cash flow of -$583.9 million, a free-cash-flow margin of -355.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Core Scientific cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -1.16B | -347.19M | 215.96M | -144.03M | -936.80M | 576.25M | -291.15M | -455.26M | -902.16M | 210.69M | -195.69M | -41.15M |
| Net Income growth (YoY) | — | -160.25% | — | — | — | +173.51% | — | — | — | — | — | — |
| Depreciation & Amortization | 15.50M | 16.65M | 14.10M | 16.33M | 18.76M | 19.73M | 26.04M | 28.69M | 29.48M | 29.00M | 31.20M | 24.23M |
| Stock-Based Compensation | 18.24M | 17.76M | 27.93M | 29.95M | 24.17M | 16.18M | 23.97M | 20.52M | 8.49M | -1.06M | 17.48M | 14.86M |
| Change in Working Capital | 130.09M | -10.49M | -13.94M | -197.04M | 215.94M | -11.58M | 51.34M | 337.00K | -41.22M | -20.19M | 203.63M | 29.14M |
| Operating Cash Flow | -18.93M | 249.88M | 157.51M | 131.78M | 34.00M | -45.04M | 13.80M | 5.71M | 1.20M | 22.17M | 21.70M | 5.43M |
| Capital Expenditures | -565.02M | -389.23M | -279.25M | -244.49M | -121.28M | -83.98M | -28.76M | -31.17M | -3.13M | -31.89M | -11.64M | -2.74M |
| Investing Cash Flow | -796.24M | -386.65M | -277.77M | -254.36M | -119.61M | -89.02M | -28.80M | -31.24M | -3.18M | -31.97M | 2.36M | -2.87M |
| Debt Issued | 3.28B | 995.00M | — | — | 0 | 0 | — | — | — | — | 0 | 0 |
| Debt Repaid | 0 | 0 | 0 | 0 | -4.66M | -3.96M | -12.93M | -263.54M | -14.65M | -13.70M | -18.05M | -14.23M |
| Financing Cash Flow | 2.22B | 971.38M | -21.81M | -5.32M | -31.77M | -4.20M | 598.17M | 182.22M | -15.19M | 54.36M | -18.30M | -15.38M |
| Net Change in Cash | 1.41B | 834.61M | -142.06M | -127.90M | -117.38M | -138.25M | 583.18M | 156.70M | -17.17M | 44.57M | 5.77M | -12.82M |
| Free Cash Flow | -583.95M | -139.35M | -121.74M | -112.71M | -87.28M | -129.02M | -14.95M | -25.46M | -1.93M | -9.72M | 10.06M | 2.69M |
This table shows 12 quarterly periods of Core Scientific's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CORZ's reporting calendar. What is a cash flow statement?